salirepin: isolated from Symplocos racemosa; structure in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Symplocos | genus | [no description available] | Symplocaceae | [no description available] |
ID Source | ID |
---|---|
PubMed CID | 16681676 |
CHEMBL ID | 468146 |
CHEBI ID | 139241 |
MeSH ID | M0516915 |
Synonym |
---|
CHEBI:139241 |
salirepin |
CHEMBL468146 |
26652-12-0 |
AKOS032962326 |
FS-9690 |
HY-N1317 |
CS-0016721 |
(2s,3r,4s,5s,6r)-2-[4-hydroxy-2-(hydroxymethyl)phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
Class | Description |
---|---|
glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID750063 | Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry | 2013 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11 | Anti-adipogenic activity of compounds isolated from Idesia polycarpa on 3T3-L1 cells. |
AID385238 | Inhibition of COX2 at 10 uM | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Itosides J-N from Itoa orientalis and structure - anti-COX-2 activity relationship of phenolic glycosides. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |